HRT Cycle Preparation Protocol
Estrogen Component Selection
- The American College of Obstetricians and Gynecologists recommends transdermal 17β-estradiol as the preferred estrogen due to its ability to mimic physiological serum estradiol concentrations, providing a better safety profile by avoiding hepatic first-pass effect 1
- The recommended starting dose for transdermal estradiol is 50-100 μg/day, with adjustments based on symptom control in postmenopausal women 1
- 17β-estradiol is preferred over ethinylestradiol or conjugated equine estrogens for all routes of administration due to its more favorable safety profile, as stated by the Endocrine Society 1, 2
Progestogen Component
- The American College of Obstetricians and Gynecologists recommends micronized natural progesterone as the first-choice progestogen due to its more favorable cardiovascular risk profile and better safety profile regarding thrombotic risk in women with an intact uterus 1, 2
- Alternative progestogens include medroxyprogesterone acetate (MPA) or dydrogesterone if micronized progesterone is not tolerated, according to the guidelines from the Society of Obstetricians and Gynaecologists of Canada 1, 2
Administration Regimens
- Continuous estrogen administration with progestogen added for 12-14 days every 28 days is recommended, resulting in regular withdrawal bleeding, which allows earlier recognition of pregnancy in women who may still ovulate, as suggested by the American Society for Reproductive Medicine 1
- This regimen offers advantages including minimal progestin exposure and lower rate of withdrawal bleeding, and is preferred for initial therapy in postmenopausal women 2
Special Considerations
- For women with hypertension, transdermal estradiol is strongly preferred due to its more favorable cardiovascular risk profile, as recommended by the American Heart Association 1
Common Pitfalls and Caveats
- Using HRT solely for prevention of chronic conditions is not recommended based on risk-benefit analysis, according to the US Preventive Services Task Force 3
- Women with premature ovarian insufficiency (POI) may spontaneously ovulate, making cyclic administration advantageous for pregnancy recognition, as stated by the European Society of Human Reproduction and Embryology 2